[4-[3-[4-(Hydroxymethyl)phenyl]-5-phenyl-3,4-dihydropyrazol-2-yl]phenyl] formate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-[3-[4-(Hydroxymethyl)phenyl]-5-phenyl-3,4-dihydropyrazol-2-yl]phenyl] formate
• 英文别名: [4-[3-[4-(hydroxymethyl)phenyl]-5-phenyl-3,4-dihydropyrazol-2-yl]phenyl] formate
• 化学式: C₂₃H₂₀N₂O₃
• 分子量: 372.4
• InChiKey: MEWODXDSYARBDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF
  申请人：Piazza Gary A.

  公开号：US20140171477A1

  公开（公告）日：2014-06-19

  Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved PDE5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional PDE5 inhibitors. Derivatives of celecoxib are also suitable for treating chronic inflammatory conditions, erectile dysfunction, pulmonary hypertension, congestive heart failure, and enhancement of cognitive function.
• US9388139B2
  申请人：——

  公开号：US9388139B2

  公开（公告）日：2016-07-12